Please ensure Javascript is enabled for purposes of website accessibility

Oscar Health Cuts Co-Pays on About 100 Drugs to $3

By Brian Orelli, PhD – Feb 21, 2020 at 1:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The health insurer hopes that making prescriptions affordable will keep the people it covers healthier, which should save it money in the long run.

Health insurance upstart Oscar Health is offering about 100 medications to many of its members with co-pays of $3 each. The prescriptions run the gamut from antibiotics to blood pressure medications to insulin to antidepressants.

"We came up with a list of about a hundred drugs that represent 90% of the use cases that somebody might need a prescription for," Vinod Mitta, VP of Pharmaceuticals at Oscar Health, said in a blog post on the company's website.

Lowering those co-payments means that Oscar will be picking up a greater share of the costs for those prescriptions, but the company may be able to make up the difference if the change results in a reduction in costly complications for those members later. "When people can afford to take their prescribed dosage, they're more likely to get and stay healthier," the blog post explained.

Doctor talking to a patient in an exam room

Image source: Getty Images.

Many of the drugs on the list are generics, which don't cost the insurer too much, but some branded drugs also made the list. Oscar included insulin on the $3 drug list, but excluded most of the modern insulin treatments, such as Novo Nordisk's (NVO 0.65%) Tresiba, Sanofi's (SNY -0.08%) Toujeo, and Eli Lilly's (LLY 1.17%) Humalog.

To keep from looking like the bad guys, the drug companies have cut prices for some of their insulin offerings. Novo Nordisk, for example, is offering up to three vials or two packs of FlexPen, FlexTouch, and Penfil pens for $99 and has launched authorized generics of some of its other insulin medications. Sanofi did even better, offering up to 10 boxes of pens or vials per month for $99. And Eli Lilly sells a version of its Humalog insulin at 50% of the branded cost, and plans to expand its half-off selection with additional offerings.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$37.22 (-0.08%) $0.03
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$311.10 (1.17%) $3.60
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
$95.90 (0.65%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.